3.70
-0.18
(-4.64%)
May 22 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 3.70 - 3.97 |
| 52 week | 2.66 - 5.51 |
| Open | 3.87 |
| Vol / Avg. | 671,582.00/774,039.00 |
| Mkt cap | 296.07M |
| P/E | - |
| Div/yield | - |
| EPS | -0.30 |
| Shares | 80.02M |
| Beta | 1.44 |
| Inst. own | 52% |
Events
Jul 29, 2013
Q2 2013 Curis, Inc. Earnings Release
May 6, 2013
Q1 2013 Curis, Inc. Earnings Release
May 1, 2013
Curis, Inc. at Needham Healthcare Conference
Apr 30, 2013
Q1 2013 Curis, Inc. Earnings Conference Call
Apr 22, 2013
Curis, Inc. at Biotechnology Industry Organization (BIO) International Convention
Apr 5, 2013
Curis, Inc. at BioCentury Publications Future Leaders in the Biotech Industry Conference
Mar 18, 2013
Curis, Inc. at Roth Conference
Mar 4, 2013
Curis, Inc. at Cowen Health Care Conference
Feb 26, 2013
Curis, Inc. at RBC Capital Markets' Healthcare Conference
Feb 25, 2013
Curis, Inc. at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -569.44% | -96.73% |
| Operating margin | -500.02% | -109.71% |
| EBITD margin | - | -108.96% |
| Return on average assets | -29.52% | -27.84% |
| Return on average equity | -61.70% | -44.28% |
| Employees | 33 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).
Officers and directors
| James R. McNab Jr. | Independent Chairman of the Board | |
| Ali Fattaey Ph.D. | President, Chief Operating Officer | |
| Daniel R. Passeri J.D. | Chief Executive Officer, Director | |
| Michael P. Gray | Chief Financial Officer | |
| Mark W. Noel | Vice President - Technology Management and Intellectual Property | |
| Maurizio Voi M.D. | Chief Medical Officer, Chief Development Officer | |
| Kenneth J. Pienta M.D. | Director | |
| Martyn D. Greenacre | Independent Director | |
| Kenneth I. Kaitin Ph.D. | Independent Director | |
| Robert E. Martell M.D., Ph.D. | Independent Director |
